Securian Asset Management Inc. decreased its stake in shares of DaVita Inc. (NYSE:DVA – Get Rating) by 6.3% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 5,008 shares of the company's stock after selling 338 shares during the quarter. Securian Asset Management Inc.'s holdings in DaVita were worth $566,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Johnson Financial Group Inc. purchased a new stake in DaVita during the 4th quarter worth about $27,000. CWM LLC boosted its stake in shares of DaVita by 154.1% during the 1st quarter. CWM LLC now owns 432 shares of the company's stock worth $49,000 after purchasing an additional 262 shares during the last quarter. FourThought Financial LLC grew its holdings in shares of DaVita by 49.6% during the first quarter. FourThought Financial LLC now owns 510 shares of the company's stock worth $56,000 after buying an additional 169 shares in the last quarter. Cullen Frost Bankers Inc. acquired a new position in shares of DaVita in the fourth quarter valued at approximately $74,000. Finally, Quent Capital LLC purchased a new position in shares of DaVita during the fourth quarter valued at approximately $118,000. 87.47% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DaVita

In other news, Director Barbara J. Desoer sold 2,320 shares of the company's stock in a transaction dated Friday, June 3rd. The stock was sold at an average price of $97.42, for a total value of $226,014.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other DaVita news, Director Barbara J. Desoer sold 2,320 shares of the company's stock in a transaction that occurred on Friday, June 3rd. The stock was sold at an average price of $97.42, for a total value of $226,014.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael David Staffieri acquired 20,000 shares of the company's stock in a transaction dated Thursday, June 23rd. The shares were purchased at an average price of $77.70 per share, for a total transaction of $1,554,000.00. Following the purchase, the chief operating officer now directly owns 61,190 shares of the company's stock, valued at $4,754,463. The disclosure for this purchase can be found here. 1.00% of the stock is owned by insiders.

Analyst Ratings Changes

DaVita Stock Performance

DaVita stock opened at $83.41 on Friday. The company has a debt-to-equity ratio of 8.53, a current ratio of 1.29 and a quick ratio of 1.25. DaVita Inc. has a 12 month low of $74.97 and a 12 month high of $136.48. The company has a market cap of $7.89 billion, a price-to-earnings ratio of 9.93, a price-to-earnings-growth ratio of 1.04 and a beta of 1.19. The stock's 50-day moving average is $87.96 and its 200-day moving average is $103.66.

DaVita (NYSE:DVA – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported $1.61 earnings per share for the quarter, missing analysts' consensus estimates of $1.85 by ($0.24). DaVita had a net margin of 7.78% and a return on equity of 78.24%. The business had revenue of $2.82 billion for the quarter, compared to analyst estimates of $2.89 billion. During the same period last year, the firm earned $2.09 earnings per share. The company's quarterly revenue was down .1% on a year-over-year basis. Equities analysts anticipate that DaVita Inc. will post 7.8 earnings per share for the current year.

About DaVita

(Get Rating)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Read More

• Get a free copy of the StockNews.com research report on DaVita (DVA)
• Can International Business Machines Recover After Its Sell-Off?
• Wingstop And Hershey Are Two Food Stocks Overcoming Inflation
• Ford Stock Rallies As EV Strategy Takes Center Stage
• Should High Yield Altria Be In Your Portfolio?
• Is Keurig-Dr. Pepper A Value Worth Buying?

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Get Rating).

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.